Ultragenyx Pharmaceutical Inc. (RARE) News
Filter RARE News Items
RARE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RARE News Highlights
- For RARE, its 30 day story count is now at 6.
- Over the past 19 days, the trend for RARE's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- AMP, LI and UL are the most mentioned tickers in articles about RARE.
Latest RARE News From Around the Web
Below are the latest news stories about ULTRAGENYX PHARMACEUTICAL INC that investors may wish to consider to help them evaluate RARE as an investment opportunity.
13 Most Promising Future Stocks To Buy According To Hedge FundsIn this piece, we will take a look at the 13 most promising stocks to buy according to hedge funds. If you want to skip our overview of the latest stock market news, then you can take a look at the 5 Most Promising Future Stocks To Buy. Investing, for the most part, is all […] |
Ultragenyx to Pay $6 Million to Settle Alleged False Medicare, Medicaid ClaimsThe Justice Department alleges Ultragenyx paid for free genetic tests for patients, and bought test results, to induce prescriptions of its drug Crysvita. |
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NOVATO, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 30,325 restricted stock units of the company’s common stock to eight newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Em |
Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)For the first time, paediatric patients aged 5-11 years with HoFH in the EU have access to a first-in-class medicine to treat an ultrarare, inherited form of high cholesterolNOVATO, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the European Commission (EC) has extended the approval of Evkeeza® (evinacumab) as an adjunct to diet and other lipid-lowering therapies to treat children aged 5 to 11 years with homozygous familial hyperchole |
Wells Fargo starts Ultragenyx coverage with overweight ratingMore on Ultragenyx Pharmaceutical |
Ultragenyx to Participate at Investor Conferences in November6th Annual Evercore ISI HealthCONx on November 28 in Miami Piper Sandler 35th Annual Healthcare Conference on November 29 in New York City NOVATO, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that management, will participating in two upcoming investor conferences. 6th Annual Evercore ISI Healt |
Ultragenyx to Participate in the Jefferies London Healthcare ConferenceNOVATO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's chief executive officer and president, will participate in a fireside chat at the upcoming Jefferies London Healthcare Conference on Tuesday, November 14, 2023, at 12:30 p.m. GMT. The live and a |
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q3 2023 Earnings Call TranscriptUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q3 2023 Earnings Call Transcript November 2, 2023 Ultragenyx Pharmaceutical Inc. misses on earnings expectations. Reported EPS is $-2.23 EPS, expectations were $-2.08. Operator: Good afternoon, and welcome to the Ultragenyx Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. At the end […] |
12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge FundsIn this article we present the list of 12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds. Click to skip past our discussion of the biotech space and straight to the 5 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds. Alkermes plc (NASDAQ:ALKS), Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) and ImmunoGen, Inc. […] |
Ultragenyx (RARE) Q3 Earnings and Revenues Miss EstimatesUltragenyx (RARE) reports weaker-than-expected third-quarter 2023 results, missing earnings and sales estimates. Management reiterates the 2023 financial outlook. |